What is androgenetic alopecia and how can it be treated?

Androgenetic alopecia, also known as male and female pattern hair loss, affects half of the male population and a quarter of the female population by the age of 50, making it the most common cause of hair loss globally.

What is Androgenetic Alopecia?

Generally, androgens are hormones that primarily stimulate the development of bones, muscles, and secondary sexual characteristics in both genders. These include the deepening of the voice, maturation of sexual organs and growth of hair in specific areas of the body such as the face, chest, armpits, and pubic region. However, androgens can also be responsible for the transformation of the androgen‐sensitive hair follicles at the frontal area or vertex region of the scalp. In androgenetic alopecia, these hair follicles in fact get smaller over time (miniaturization) which causes thinning and consequent the falling of hair strands.

How does it manifest itself and why?

Androgenetic alopecia can manifest itself at any time after puberty and is usually a disease that progresses slowly. As time passes the number of hair follicles in the telogen phase (resting phase of hair growth) increases, resulting in a shortened anagen (growth) phase for the patient, and therefore a shorter life for the hair strand. 

alt=”Androgenetic Alopecia” width=”468″ height=”401″ data-wp-pid=”1795″ />In men, Androgenetic alopecia follows a receding hairline pattern that ultimately results in loss of hair at the vertex or the top of the head. Differently, in women the vertex is the first part to be affected with signs of hair thinning. As the hairline does not usually recede, this condition, unlike it doesn’t in men, rarely leads to complete baldness in women.

Although male pattern hair loss is associated with a combination of genetic predisposition and the hormone dihydrotestosterone, the cause of androgenetic alopecia in females remains unclear.  

What are the treatment options available?

There are several popular treatment options currently available for the management of Androgenetic alopecia. Some of the most common and effective solutions include:


Cedarwood, lavender, thyme, and rosemary oils have their unique beneficial role depending on different types of hair, as well as having relatively low – to no toxic – side effects. A study published in 2015 compared the effectiveness of rosemary oil to the medicinal minoxidil in individuals with androgenic type hair loss, and found that after six months, both treatments resulted in significant hair growth. However, the group assigned with rosemary oil treatment did not report any side effects to the treatment, unlike the minoxidil exposed group. 

Saw palmetto is an herbal supplement known for its receptor blocking activity towards the hormone linked to hair loss. Its use is popular among men who avoid finasteride and other medicinal preparations due to their possible side effects. A clinical trial showed high positive outcomes (up to 60%) from the treatment of saw palmetto in men aging 23- 64 years of age.



Currently, minoxidil and finasteride are the only two FDA-approved medicinal treatments for androgenetic  hair loss. Minoxidil has proven advantages of slowing down Androgenetic alopecia and in some cases of also inducing new hair growth.

It works by prolonging the anagen phase of hair growth by activating potassium channels in the hair follicle, which results in an increased prostaglandin production that promotes hair growth. At least six months of treatment is estimated to be required to prevent further hair loss and to initiate hair growth.

Dermatologists usually suggest a 2% concentration preparation of minoxidil for women and a 5% concentration for men suffering from androgenetic alopecia.


Finasteride (Propecia) is a once-daily oral medication that is considered a gold standard treatment for Androgenetic alopecia in men. It inhibits the enzyme (5-alpha reductase inhibitor) that stimulates hair loss in men along with causing an increase in hair retention, the weight of hair, and regrowth.

A five year clinical trial on Finasteride concluded a 90% efficacy rate in the subjects in terms of hair gain and maintenance of present hair strands over the duration of the trial.

This drug is found to be highly effective in younger men in comparison to older men, and may not produce any significant results in men over the age of 60. 

Rare side effects observed with finasteride use include decreased libido, and sexual function and an increased risk of prostate cancer. Results are visible after six weeks of initiating treatment. However, once the treatment is stopped, hair loss is mostly seen to resume.


Dutasteride belongs to the same class of drugs as finasteride with the only difference being its effectiveness in blocking testosterone conversion into Dihydrotestosterone (DHT). Finasteride is the older of the two drugs and is the only one approved by the FDA for the treatment of hair loss in men, whereas dutasteride is FDA approved for the treatment of benign prostatic hyperplasia. A study published in 2005 proved dutasteride to have more potential in blocking testosterone conversion (around 98% of DHT) on similar dosing as compared to finasteride (around 70% of DHT). Administration of dutasteride to women is contraindicated as it can affect the normal development of reproductive organs in male fetuses due to decreased DHT levels.


Low-Level Laser Therapy is known to promote effective hair growth in patients with androgenetic alopecia along with reversing the miniaturizing process this is typical of this type of hair loss. Multiple studies strongly recommend and support the effectiveness of LLLT for the treatment of androgenetic alopecia, as it’s a safe, painless and non-invasive procedure.

Surgical procedures to manage androgenetic alopecia can range from scalp flaps, hair loss reduction, follicle transplants, and hairline lowering options. Surgical procedures are generally expensive, painful, and also carry a risk of infections and secondary scarring. However, surgery is frequently sought by individuals who are self-conscious about their physical appearance. The transplanted hair falls out a few weeks after the surgery, but the hair that grows back in its place is strong and permanent. 

Clinical studies have shown that approximately 85-95% of all implanted bulbs grow without problems in the transplanted area. This high percentage indicates that hair transplants, in general, have a high success rate. The visible results of a surgical procedure can be seen after six to eight months of surgery. 


Find out more about what the reasons behind YOUR hairloss may be, and how to effectively treat it on other sections of Trichology.com



Vary Jr JC. Selected disorders of skin appendages–acne, alopecia, hyperhidrosis. The Medical Clinics of North America. 2016 Jan 19;99(6):1195-211.

Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology. 2008 Oct 1;59(4):547-66.

Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, Webster SB, Whitaker DC, Butler B. Guidelines of care for androgenetic alopecia. American Academy of Dermatology. Journal of the American Academy of Dermatology. 1996 Sep;35(3 Pt 1):465.

Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. British Journal of Dermatology. 2001 Feb;144(2):297-304.

Kaplan SA. Marked Suppression of Dihydrotestosterone in Men With Benign Prostatic Hyperplasia by Dutasteride, a Dual 5Alpha-Reductase Inhibitor. The Journal of Urology. 2005 Feb;173(2):514-5.

Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology. 2008 Oct 1;59(4):547-66.

Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology. 2004 Apr 1;50(4):541-53.

Diani AR, Mulholland MJ, Shull KL, Kubicek MF, Johnson GA, Schostarez HJ, Brunden MN, Buhl AE. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. The Journal of Clinical Endocrinology & Metabolism. 1992 Feb 1;74(2):345-50.

Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-α-reductase in the treatment of androgenetic alopecia. The Journal of Alternative & Complementary Medicine. 2002 Apr 1;8(2):143-52.

Murugusundram S. Serenoa repens: does it have any role in the management of androgenetic alopecia?. Journal of cutaneous and aesthetic surgery. 2009 Jan;2(1):31

Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed. 2015;13(1):15-21.

Panchaprateep R, Pisitkun T, Kalpongnukul N. Quantitative proteomic analysis of dermal papilla from male androgenetic alopecia comparing before and after treatment with lowlevel laser therapy. Lasers in surgery and medicine. 2019 Sep;51(7):600-8.